Advaxis, Merck to combine immunotherapies for prostate cancer

Advaxis jumped 23.1% to $4 per share on 25 August after the company announced a second partnership to test its immunotherapy platform in combination with a programmed cell death-1 (PD-1) inhibitor, the Merck & Co biologic pembrolizumab (MK-3475).